Distinction of hepatocellular adenoma from hepatocellular carcinoma with and without cirrhosis using E-cadherin and matrix metalloproteinase immunohistochemistry

Modern Pathology

Volumn 22, Issue 8, 2009, Pages 1113-1120

  Tretiakova, Maria S ^a   Hart, John ^a   Shabani Rad, Meer Taher ^b   Zhang, Jianguo ^c   Gao, Zu Hua ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adenoma; Cirrhosis; E cadherin; Hepatocellular carcinoma; Metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; STROMELYSIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CELL;

EID: 68249092505     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.75     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Chen CJ, Wang LY, Lu SN, et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996;24:38-42.
3. Harris CC. Hepatocellular carcinogenesis: recent advances and speculations. Cancer Cells 1990;2:146-148.
4. Johnson PJ, Williams R. Cirrhosis and the etiology of hepatocellular carcinoma. J Hepatol 1987;4:140-147.
5. Saito I, Miyanmura T, Ohabayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-6549.
6. Nazeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinicohistopathologic study of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
7. Evert M, Dombrowski F. Hepatocellular carcinoma in the non-cirrhotic liver. Pathologe 2008;29:47-52.
8. Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002;161(Suppl 1): S46-S49.
9. Edmonston H, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraception. N Engl J Med 1976;294:470-472.
10. Kew MC. Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology 1989;97:136-139.
11. Okuda K, Nakashima T, Koijiro M, et al. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989;97:140-146.
12. Gao ZH. Predictive markers for the recurrence of hepatocellular carcinoma. J Surg Oncol 2005;92: 274-275.
13. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005;18:1417-1423.
14. Ferrel LD. Hepatocellular carcinoma arising in a focus of multilobular adenoma: a case report. Am J Surg Pathol 1993;17:525-529.
15. Brikedal-hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
16. Docherty AJP, O'Conell J, Crabbe T, et al. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol 1992;10:200-207.
17. Senta A, Itoh F, Yamamoto H, et al. Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin Exp Metastasis 1998;16:313-321.
18. Yoshimoto M, Itoh F, Yamamoto H, et al. Expression of MMP-7 (Pump-1) mRNA in human colorectal cancers. Int J Cancer 1993;54:614-618.
19. Wijnhoven BPL, Dinjens WNM, Pignatelli M. E-cadherin-cateinin cell-cell adhesion complex and human cancer. Br J Surg 2000;87:992-1005.
20. Gao ZH, Trekiakova M, Liu WH, et al. Association of E-cadherin, matrix metalloproteinases and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol 2006;19:533-540.
21. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma In: Hamilton SR and Aaltonen LA (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. IARC Press: Lyon, 2000;165-166.
22. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994;308:1552.
23. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39: 561-577.
24. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-321.
25. Berx G, Becker KF, Hofler H, et al. Mutations of human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-237.
26. Berx G, Cleton-Jansen AM, Noller F, et al. E-cadherin is a tumor/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14:6107-6115.
27. Inayoshi J, Ichida T, Sugitani S, et al. Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment. J Gastroenterol Hepatol 2003;18:673-677.
28. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001;7:594-599.
29. Saeki Y, Hazeki K, Matsumoto M, et al. Correlation between metastatic potency and the down-regulation of E-cadherin in the mouse hepatoma cell lines G-1 and G-5. Oncol Rep 2000;7:731-735.
30. Shinoyama Y, Hirohashi S. Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin in an indifferentiated carcinoma. Cancer Lett 1991;57:131-135.
31. Lichtinghagen R, Helmbrecht T, Arndt B, et al. Expression pattern of matrix metalloproteinases in human liver. Eur J Clin Chem Clin Biochem 1995;33:65-71.
32. Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis. Int J Oncol 1993;2:861-872.
33. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000;36:1621-1630.
34. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
35. Yang W, Arii S, Gorrin-Rivas MJ, et al. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 2001;91:1277-1283.
36. Arri S, Mise M, Harada T, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996;24:316-322.
37. Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002;97:425-431.
38. Grigioni WF, Garisa S, D'Errico A, et al. Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol 1991;138:647-654.
39. Sakamoto Y, Mafune K, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 2000;17:237-243.
40. Yamamoto H, Itoh F, Adachi Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 1997;112:1290-1296.
41. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-136.
42. Saariaho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995;105:190-196.
43. Wilson CL, Hepper KJ, Rudolph LA, et al. The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol Biol cell 1995;6:851-869.
44. Ishii Y, Nakasato Y, Kobayashi S, et al. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003;22:461-470.
45. Ozaki I, Mizuta T, Zhao G, et al. Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res 2000;60: 6519-6525.
46. Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenas B) in hepatocellular carcinoma. Hepatology 1996;24:1058-1062.
47. Cheng JC, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-κ B signal transduction pathway. Oncogene 2006;25:7009-7018.
48. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBX induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004;18: 1123-1125.
49. Hsiang CY, Wu SL, Chen JC, et al. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-κ B and activator protein 1 signaling pathway in human hepatocellular carcinoma cells: association with invasive potential. Toxicol Lett 2007;171:78-86.
50. Kim ES, Kim MS, Moon A. TGF-β-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004;25:1375-1382.
51. Liu S, Crepin M, Liu JM, et al. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 2002;293: 1174-1182.